Kala制药(KALA)

1.97 -0.01 -0.5051%

今开:1.95昨收:1.98
最高:2.05 最低:1.94
涨停价:0.0跌停价:0.0
总市值:1.27993059E8

Kala制药的热门评论

Kala制药(KALA)2019-04-13 10:40

$Kala制药(KALA)$ DEF 14A - Other definitive proxy statements Filed: 2019-04-12 AccNo: 0001558370-19-002956 Size: 991 KB 网页链接查看全文

Kala制药(KALA)2019-04-13 10:40

$Kala制药(KALA)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-04-12 AccNo: 0001558370-19-002961 Size: 194 KB 网页链接查看全文

Kala制药(KALA)2019-03-12 10:40

$Kala制药(KALA)$ 8-K - Current report Filed: 2019-03-11 AccNo: 0001558370-19-001781 Size: 278 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接查看全文

Kala制药(KALA)2019-03-12 22:50

$Kala制药(KALA)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-03-12 AccNo: 0001558370-19-001825 Size: 11 MB 网页链接查看全文

Kala制药(KALA)2019-03-12 22:50

$Kala制药(KALA)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2019-03-12 AccNo: 0001558370-19-001827 Size: 161 KB 网页链接查看全文

Kala制药(KALA)2019-03-06 19:35

$Kala制药(KALA)$ 美东时间 2019-03-11 盘后 披露财报,预期EPS -0.52 网页链接查看全文

Kala制药(KALA)2019-02-14 11:05

$Kala制药(KALA)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-13 AccNo: 0001193125-19-037954 Size: 137 KB 网页链接查看全文

Kala制药(KALA)2019-02-13 23:45

$Kala制药(KALA)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-13 AccNo: 0001172661-19-000440 Size: 86 KB 网页链接查看全文

Kala制药(KALA)2019-02-13 10:00

$Kala制药(KALA)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-12 AccNo: 0000902219-19-000317 Size: 33 KB 网页链接查看全文

Kala制药(KALA)2019-02-13 10:00

$Kala制药(KALA)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-12 AccNo: 0000846087-19-000053 Size: 18 KB 网页链接查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Kala制药的最新评论

首次持股声明

Kala制药(KALA)10-20 04:12

$Kala制药(KALA)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-21-004906 Size: 10 KB 网页链接查看全文

持股变动声明

Kala制药(KALA)10-20 04:12

$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-21-004907 Size: 5 KB 网页链接查看全文

美股滚雪球10-19 15:48

$Esperion(ESPR)$ 裁员40%,$Kala制药(KALA)$ 药物获批后,快跌成毛票,biotech的商业化比研发还难。$百济神州(BGNE)$的商业化不一定会比其他biotech差,但一定不会比大药企好。查看全文

当期报告

Kala制药(KALA)10-18 20:12

$Kala制药(KALA)$ 8-K Current report, item 5.02 Accession Number: 0001558370-21-013248 Act: 34 Size: 159 KB 网页链接查看全文

超过5%股东持股披露「修订」

Kala制药(KALA)10-15 05:06

$Kala制药(KALA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000947871-21-001065 Act: 34 Size: 76 KB 网页链接查看全文

季度财报

Kala制药(KALA)08-06 04:06

$Kala制药(KALA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-21-010528 Act: 34 Size: 7 MB 网页链接查看全文

当期报告

Kala制药(KALA)08-05 19:06

$Kala制药(KALA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-21-010375 Act: 34 Size: 385 KB 网页链接查看全文

Takeabreak07-26 21:10

$Kala制药(KALA)$ Symphony Health sales and volume estimates are as follows: For the week ending July 16, 2021: INVELTYS: Approximately $828k (MBS Dollars) in sales and 2,985 pack units (both up +20.7% week-over-week) -About 74% were from new prescriptions and 26% from refill...查看全文

Takeabreak07-22 11:50

$Karyopharm(KPTI)$ $G1治疗(GTHX)$ $Kala制药(KALA)$ BTAI. Value destroyers?? Commercialization is more risky. Lesson learned??? Or patience is a virtue ??查看全文

Spica07-18 19:54

回复@Takeabreak: 我问了下一位做干眼症的朋友,他是这么回复的“”Eysuvis 应该还不错,但不会成为重磅。重要的原因:lotemax一直被off label用作治疗干眼,$Kala制药(KALA)$ 只是改了一个剂型,把off label变成approved。Lotemax医生可以随便开的,会一定程度限制了Eysuvis销售“//@Takeabreak:...查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Kala制药的公告

首次持股声明

$Kala制药(KALA)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-21-004906 Size: 10 KB 网页链接

持股变动声明

$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-21-004907 Size: 5 KB 网页链接

当期报告

$Kala制药(KALA)$ 8-K Current report, item 5.02 Accession Number: 0001558370-21-013248 Act: 34 Size: 159 KB 网页链接

超过5%股东持股披露「修订」

$Kala制药(KALA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000947871-21-001065 Act: 34 Size: 76 KB 网页链接

季度财报

$Kala制药(KALA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-21-010528 Act: 34 Size: 7 MB 网页链接

当期报告

$Kala制药(KALA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-21-010375 Act: 34 Size: 385 KB 网页链接

$Kala制药(KALA)$ 内部交易: 2021-06-29,CHIEF SCIENTIFIC OFFICER,Chen Hongming ,卖出,5548普通股, $5.56

持股变动声明

$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-21-003271 Size: 5 KB 网页链接

$Kala制药(KALA)$ 内部交易: 2021-06-28,CHIEF EXECUTIVE OFFICER,Iwicki Mark T ,卖出,7586普通股, $5.77

$Kala制药(KALA)$ 内部交易: 2021-06-28,CHIEF FINANCIAL OFFICER,Reumuth Mary ,卖出,2452普通股, $5.77

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24